Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Stage of deal | Other | Late | Mid | Early |
|---|---|---|---|---|
| Q2 2020 | 22% | 5% | 22% | 51% |
| Q1 2020 | 18% | 5% | 22% | 55% |
| Q4 2019 | 15% | 7% | 19% | 59% |
| Q3 2019 | 15% | 3% | 17% | 66% |
| Q2 2019 | 14% | 7% | 19% | 60% |
| Q1 2019 | 14% | 5% | 16% | 64% |
| Q4 2018 | 18% | 4% | 16% | 62% |
| Q3 2018 | 20% | 6% | 15% | 59% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
August 2020
More information
Region
Worldwide
Survey time period
Q2 2018 to Q2 2020
Supplementary notes
* 鈥淓arly-stage鈥 includes convertible note, angel, seed, and Series A rounds. 鈥淢id-stage鈥 includes Series B and Series C rounds. 鈥淟ate-stage鈥 includes Series D,
Series E+, growth equity, and private equity rounds. 鈥淥ther鈥 includes unattributed and corporate minority rounds.
Percentage points missing/exceeding 100 percent are probably due to rounding.
Citation formats
